调节PRC1促进胰腺癌的抗癌作用
Hajin Lee1, An-Na Bae1, Huiseong Yang1
1Department of Anatomy, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea.
Cancers
|October 16, 2024
概括
在胰腺癌中准PRC1显示出有前途. 过度表达的PRC1与免疫力低下相关,但使其沉默会抑制癌症生长并改善药物敏感性,这表明PRC1是治疗点.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
背景情况:
- 胰腺癌是全球癌症死亡的主要原因之一.
- 胰腺癌进展的确切调节机制尚未完全理解.
- 确定新的治疗点对于改善患者的治疗结果至关重要.
研究的目的:
- 研究PRC1在胰腺癌中的临床意义和功能作用.
- 评估PRC1作为胰腺癌治疗的潜在治疗标.
主要方法:
- 临床数据的生物信息分析,以评估PRC1表达.
- 在体外基于细胞的测定包括活力,伤口愈合和药物敏感性.
- 通过RNA干扰 (siRNA) 在胰腺癌细胞中抑制PRC1的表达.
主要成果:
- 在胰腺癌组织和细胞系中,PRC1显著过度表达.
- 高PRC1表达与CD4+T细胞透负相关,这对抗癌免疫很重要.
- PRC1的表达与已知的胰腺癌标志物正相关.
- 沉默PRC1抑制癌细胞的增殖,活力,并提高对化疗的敏感性.
结论:
- 在胰腺癌中,PRC1是潜在的生物标志物和治疗点.
- 向PRC1可能通过增加T细胞透来增强抗瘤免疫反应.
- 抑制PRC1可能是抑制胰腺癌进展和化学敏感性的可行策略.
更多相关视频
07:08Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
Published on: February 2, 2024
734
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
18.7K
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Induced Pluripotent Stem Cells
3.9K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
3.9K
